Scientists in Australia begin preclinical study...

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Scientists in Australia begin preclinical study...

Post by MSUK » Wed Jan 24, 2018 5:47 am

Scientists in Australia begin preclinical study that may help halt MS progression

Researchers from Monash University in Australia are set to conduct a large study into a drug that may one day help halt the progression of multiple sclerosis (MS)...Read more - http://www.ms-uk.org/scientists-austral ... rogression

Image
MS-UK - http://www.ms-uk.org/

User avatar
NHE
Volunteer Moderator
Posts: 5316
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Scientists in Australia begin preclinical study...

Post by NHE » Wed Jan 24, 2018 11:18 pm

MSUK wrote:Scientists in Australia begin preclinical study that may help halt MS progression

Researchers from Monash University in Australia are set to conduct a large study into a drug that may one day help halt the progression of multiple sclerosis (MS)...Read more - http://www.ms-uk.org/scientists-austral ... rogression
The compound beind studied, 3,5-diiodothyropropionic acid, is a thyroid hormone analog. I wasn't able to find any published studies of its use in MS, but it has been studied in congestive heart failure (CHF) patients.

https://www.ncbi.nlm.nih.gov/pubmed?ter ... ailsSearch

User avatar
Scott1
Volunteer Moderator
Posts: 1485
Joined: Wed Oct 22, 2008 2:00 pm

Re: Scientists in Australia begin preclinical study...

Post by Scott1 » Thu Jan 25, 2018 2:01 am

Hi,

Might not be as easy as it sounds. https://academic.oup.com/jcem/article/95/3/1349/2597364

Regards,

User avatar
NHE
Volunteer Moderator
Posts: 5316
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Scientists in Australia begin preclinical study...

Post by NHE » Thu Jan 25, 2018 2:49 am

Scott1 wrote:Hi,

Might not be as easy as it sounds. https://academic.oup.com/jcem/article/95/3/1349/2597364
In conclusion, this phase II trial in patients treated with the thyroid hormone analog DITPA has shown that the agent has significant LDL cholesterol-lowering properties and that it can induce significant weight loss. However, DITPA’s actual clinical safety and efficacy would have to be demonstrated in a more definitive trial using a lower drug dosage that might be better tolerated. Whether its profile of adverse effects, which led to a high dropout rate and included apparently unfavorable effects on markers of bone metabolism, would justify such further investigation is arguable. However, this demonstration of potentially beneficial actions of a thyromimetic agent suggests the potential value of this drug class in patients with dyslipidemia and obesity.
In December 2008, Titan Pharmaceutical discontinued its development of DITPA...
So, why are they testing DITPA in MS :?:

Post Reply
  • Similar Topics
    Replies
    Views
    Last post